AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
AN2 Therapeutics, Inc. announced the grant of inducement equity awards to two newly hired employees.
Stocks · News reference
AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AN2 Therapeutics to Present Phase 2 Trial Design for Epetraborole in Polycythemia Vera
AN2 Therapeutics announced it will present the design of its planned Phase 2 clinical trial for epetraborole in patients with polycythemia vera at the 18th International Congress on Myeloproliferative Neoplasms.
AN2 Therapeutics to Participate in Upcoming Investor Conferences
AN2 Therapeutics announced its upcoming participation in investor conferences.
AN2 Therapeutics To Present Planned Phase 2 Trial Design For Epetraborole In Polycythemia Vera On October 29